Drug profile · INN
gilteritinib fumarate
XOSPATA
gilteritinib fumarate (XOSPATA) is a tyrosine-protein kinase receptor flt3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — gilteritinib fumarate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
gilteritinib fumarate (XOSPATA) is a tyrosine-protein kinase receptor flt3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase receptor FLT3 inhibitor
Primary target: Receptor-type tyrosine-protein kinase FLT3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is gilteritinib fumarate?
gilteritinib fumarate (XOSPATA) is a tyrosine-protein kinase receptor flt3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for gilteritinib fumarate?
XOSPATA is a marketed brand name for gilteritinib fumarate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of gilteritinib fumarate?
gilteritinib fumarate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.